Avalon GloboCare Secures Patent for CAR-T Cell Tech in Hong Kong
Avalon GloboCare's Breakthrough in CAR Technology Patent
Avalon GloboCare Corp. (NASDAQ: ALBT) has reached a major milestone with the approval of a new standard patent by the Hong Kong Intellectual Property Department. This patent grants long-term protection for its cutting-edge CAR-T and CAR-Natural Killer (NK) cell technology, reinforcing Avalon's commitment to innovation in cellular therapies.
Significant Patent Details
The patent, designated as HK40074322, stems from a foundational Chinese patent and secures a protective term of 20 years. This crucial step in the company's global intellectual property strategy illustrates Avalon's dedication to safeguarding its pioneering technologies in the competitive landscape of advanced therapeutic solutions.
Collaborative Innovations with Strategic Partners
Working alongside Arbele Limited, a Hong Kong-based strategic partner, Avalon has co-developed this technology that significantly advances CAR-based therapies. This patent complements existing protections Avalon's secured in the US and other jurisdictions under the Patent Cooperation Treaty, enhancing brand credibility and technological trust.
Technological Advantages Offered
The patented CAR-T and CAR-NK cell technology presents groundbreaking enhancements designed to optimize the development and effectiveness of these cells. Some key innovations include:
Bispecific Anti-CD19xCD22 CAR Design
This design targets two critical antigens, CD19 and CD22, providing a strategic advantage in combatting hematological malignancies. Its dual-action approach aims to minimize the common issue of tumor cells evading treatment through antigen loss, thus improving therapeutic outcomes.
Localized Cytokine Induction
Avalon’s technology aims to stimulate immune responses specifically at tumor sites. This localized approach is anticipated to enhance cell proliferation and persistence while also stimulating the patient's immune system, thereby boosting therapeutic efficacy.
Avalon’s Perspective on the Patent Achievement
David Jin, M.D., Ph.D., Avalon’s CEO expressed enthusiasm about securing this patent in Hong Kong. He referred to it as a pivotal expansion of Avalon's global intellectual property portfolio, stating, "With this patent protection extending to 2040, we are well-positioned to enhance our offerings in the evolving field of cell-based immunotherapy." This patent underscores the company’s ambitious vision and strategic growth in health tech.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. is at the forefront of developing precision diagnostic products and innovative solutions in the cellular therapy sector. Aside from its CAR technology, Avalon is recognized for its KetoAir™ breathalyzer device, which is FDA registered as a Class I medical device and represents Avalon's comprehensive approach to diagnostic advancements. Additionally, Avalon maintains a focus on its intellectual property development and operates commercial real estate.
For more insights into Avalon's innovative work and their product offerings, visit www.avalon-globocare.com.
Frequently Asked Questions
What is the primary advancement of Avalon's new patent?
The patent enhances CAR-T and CAR-NK cell therapies, significantly improving their effectiveness and durability.
Who are Avalon's strategic partners involved in this technology?
Arbele Limited, based in Hong Kong, is a key strategic partner in developing this innovative cell therapy technology.
What are the unique features of the CAR technology patent?
It includes a bispecific design targeting two antigens and a localized induction of cytokines, enhancing immune response at tumor sites.
How long is the patent valid for Avalon's CAR technology?
The patent is protected for a duration of 20 years, extending until 2040.
What other products does Avalon GloboCare develop?
Avalon also focuses on precision diagnostic products like the KetoAir™ breathalyzer, showcasing its range in healthcare innovation.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.